Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in Eur Respir J

Retrieve available abstracts of 49 articles:
HTML format
Text format



Single Articles


    May 2018
  1. SUN YQ, Brumpton BM, Bonilla C, Lewis SJ, et al
    Serum 25-hydroxyvitamin D levels and risk of lung cancer and histologic types: a Mendelian randomisation analysis of the HUNT study.
    Eur Respir J. 2018 May 10. pii: 13993003.00329-2018.
    PubMed     Text format     Abstract available


    April 2018
  2. RAMI-PORTA R, Call S, Dooms C, Obiols C, et al
    Lung cancer staging: a concise update.
    Eur Respir J. 2018 Apr 26. pii: 13993003.00190-2018.
    PubMed     Text format     Abstract available


    March 2018
  3. ZUGAZAGOITIA J, Biosca M, Olivera J, Eugenia Olmedo M, et al
    Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small-cell lung cancer.
    Eur Respir J. 2018 Mar 21. pii: 13993003.02431-2017.
    PubMed     Text format    


  4. LOUBIERE S, Drezet A, Beau-Faller M, Moro-Sibilot D, et al
    Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


    December 2017
  5. DECALUWE H, Dooms C, D'Journo XB, Call S, et al
    Mediastinal staging by videomediastinoscopy in clinical N1 non-small cell lung cancer: a prospective multicentre study.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


    October 2017
  6. SUN YQ, Chen Y, Langhammer A, Skorpen F, et al
    Passive smoking in relation to lung cancer incidence and histologic types in Norwegian adults: the HUNT study.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  7. PARIS C, Do P, Mastroianni B, Dixmier A, et al
    Association between lung cancer somatic mutations and occupational exposure in never-smokers.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


    August 2017
  8. TOMASINI P, Brosseau S, Mazieres J, Merlio JP, et al
    EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


  9. GLATZER M, Rittmeyer A, Muller J, Opitz I, et al
    Treatment of limited disease small cell lung cancer: the multidisciplinary team.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


    July 2017
  10. PLUVY J, Brosseau S, Naltet C, Opsomer MA, et al
    Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment.
    Eur Respir J. 2017;50.
    PubMed     Text format    


    May 2017
  11. AAMLI GAGNAT A, Gjerdevik M, Gallefoss F, Coxson HO, et al
    Incidence of non-pulmonary cancer and lung cancer by amount of emphysema and airway wall thickness: a community-based cohort.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


    April 2017
  12. TIAN Q, Deng WJ, Li ZW
    Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patient.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  13. KHIROYA H, Moore JS, Ahmad N, Kay J, et al
    IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


  14. CALVAYRAC O, Pradines A, Pons E, Mazieres J, et al
    Molecular biomarkers for lung adenocarcinoma.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


    March 2017
  15. ZUGAZAGOITIA J, Molina-Pinelo S, Lopez-Rios F, Paz-Ares L, et al
    Biological therapies in nonsmall cell lung cancer.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


  16. LEDUC C, Antoni D, Charloux A, Falcoz PE, et al
    Comorbidities in the management of patients with lung cancer.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


  17. DE PERROT M, Dong Z, Bradbury P, Patsios D, et al
    Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


    January 2017
  18. DE-TORRES JP, Sanchez-Salcedo P, Bastarrika G, Alcaide AB, et al
    Telomere length, COPD and emphysema as risk factors for lung cancer.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  19. MCDONALD F, De Waele M, Hendriks LE, Faivre-Finn C, et al
    Management of stage I and II nonsmall cell lung cancer.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


    November 2016
  20. SHIN S, Park HY, Kim H, Kim HK, et al
    Joint effect of airflow limitation and emphysema on postoperative outcomes in early-stage nonsmall cell lung cancer.
    Eur Respir J. 2016 Nov 3. pii: ERJ-01148-2016. doi: 10.1183/13993003.01148-2016.
    PubMed     Text format     Abstract available


  21. RUANO-RAVINA A, Torres-Duran M, Kelsey KT, Parente-Lamelas I, et al
    Residential radon, EGFR mutations and ALK alterations in never-smoking lung cancer cases.
    Eur Respir J. 2016;48:1462-1470.
    PubMed     Text format     Abstract available


    September 2016

  22. "Plasma pro-surfactant protein B and lung function decline in smokers." Janice M. Leung, John Mayo, Wan Tan, C. Martin Tammemagi, Geoffrey Liu, Stuart Peacock, Frances A. Shepherd, John Goffin, Glenwood Goss, Garth Nicholas, Alain Tremblay, Michael Jo
    Eur Respir J. 2016;48:962.
    PubMed     Text format    


  23. LEE SY, Kang HG, Choi JE, Jung DK, et al
    Polymorphisms in cancer-related pathway genes and lung cancer.
    Eur Respir J. 2016 Sep 1. pii: ERJ-02040-2015. doi: 10.1183/13993003.02040-2015.
    PubMed     Text format     Abstract available


    July 2016
  24. MAK KS, van Bommel AC, Stowell C, Abrahm JL, et al
    Defining a standard set of patient-centred outcomes for lung cancer.
    Eur Respir J. 2016 Jul 7. pii: ERJ-02049-2015. doi: 10.1183/13993003.02049-2015.
    PubMed     Text format     Abstract available


  25. CIHORIC N, Tsikkinis A, Filipovic N, Jeremic B, et al
    Treatment options for isolated locoregional recurrences of nonsmall cell lung cancer after surgery: yes, radiation therapy too!
    Eur Respir J. 2016;48:276-8.
    PubMed     Text format    


    June 2016
  26. FITENI F, Anota A, Bonnetain F, Oster JP, et al
    Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
    Eur Respir J. 2016 Jun 23. pii: ERJ-01695-2015. doi: 10.1183/13993003.01695-2015
    PubMed     Text format     Abstract available


    May 2016
  27. MALHOTRA J, Malvezzi M, Negri E, La Vecchia C, et al
    Risk factors for lung cancer worldwide.
    Eur Respir J. 2016 May 12. pii: ERJ-00359-2016. doi: 10.1183/13993003.00359-2016
    PubMed     Text format     Abstract available


  28. IRIE M, Nakanishi R, Yasuda M, Fujino Y, et al
    Risk factors for short-term outcomes after thoracoscopic lobectomy for lung cancer.
    Eur Respir J. 2016 May 12. pii: ERJ-01939-2015. doi: 10.1183/13993003.01939-2015
    PubMed     Text format     Abstract available


  29. REMON J, Bonastre J, Besse B
    The 5000% case: a glimpse into the financial issue of lung cancer treatment.
    Eur Respir J. 2016;47:1331-3.
    PubMed     Text format    


    April 2016

  30. "Lung cancer survival in Norway, 1997-2011: from nihilism to optimism." Yngvar Nilssen, Trond Eirik Strand, Lars Fjellbirkeland, Kristian Bartnes and Bjorn Moller. Eur Respir J 2016; 47: 275-287.
    Eur Respir J. 2016;47:1297.
    PubMed     Text format    


    March 2016
  31. CARBONNAUX M, Souquet PJ, Meert AP, Scherpereel A, et al
    Inequalities in lung cancer: a world of EGFR.
    Eur Respir J. 2016 Mar 30. pii: ERJ-01157-2015. doi: 10.1183/13993003.01157-2015
    PubMed     Text format     Abstract available


  32. PAGES PB, Cottenet J, Mariet AS, Bernard A, et al
    In-hospital mortality following lung cancer resection: nationwide administrative database.
    Eur Respir J. 2016 Mar 10. pii: ERJ-00052-2016. doi: 10.1183/13993003.00052-2016
    PubMed     Text format     Abstract available


  33. JANSSENS A, Teugels L, Kohl S, Michielsen T, et al
    Practical tools for implementing early palliative care in advanced lung cancer.
    Eur Respir J. 2016;47:1010-2.
    PubMed     Text format    


  34. TRAVIS WD, Brambilla E, Geisinger KR
    Histological grading in lung cancer: one system for all or separate systems for each histological type?
    Eur Respir J. 2016;47:720-3.
    PubMed     Text format    


    February 2016
  35. GUILLON A, Gueugnon F, Mavridis K, Dalloneau E, et al
    Interleukin-22 receptor is overexpressed in nonsmall cell lung cancer and portends a poor prognosis.
    Eur Respir J. 2016 Feb 4. pii: ERJ-01580-2015. doi: 10.1183/13993003.01580-2015.
    PubMed     Text format    


  36. SUBOTIC D, Van Schil P, Grigoriu B
    Optimising treatment for post-operative lung cancer recurrence.
    Eur Respir J. 2016;47:374-8.
    PubMed     Text format    


  37. PRICE LC, Wort SJ
    Earlier diagnosis and international registries may improve outcomes in pulmonary tumour thrombotic microangiopathy.
    Eur Respir J. 2016;47:690-1.
    PubMed     Text format    


  38. MERAD M, Savale L, Antoun S, Vincent F, et al
    Is there hope of improving the prognosis of pulmonary tumour thrombotic microangiopathy?
    Eur Respir J. 2016;47:688-90.
    PubMed     Text format    


  39. DERKS JL, Hendriks LE, Buikhuisen WA, Groen HJ, et al
    Clinical features of large cell neuroendocrine carcinoma: a population-based overview.
    Eur Respir J. 2016;47:615-24.
    PubMed     Text format     Abstract available


  40. STEINFORT DP, Bonney A, See K, Irving LB, et al
    Sequential multimodality bronchoscopic investigation of peripheral pulmonary lesions.
    Eur Respir J. 2016;47:607-14.
    PubMed     Text format     Abstract available


    January 2016
  41. FAURE M
    Lung cancer in Europe: turning the spotlight on the biggest cancer killer.
    Eur Respir J. 2016;47:42-4.
    PubMed     Text format    


  42. PINETON DE CHAMBRUN M, Lemiale V, Azoulay E
    Lung positron emission tomography with FDG in patients with haematological malignancies and acute respiratory failure.
    Eur Respir J. 2016;47:324-7.
    PubMed     Text format    


    December 2015
  43. TORRES-DURAN M, Ruano-Ravina A, Kelsey KT, Parente-Lamelas I, et al
    Small cell lung cancer in never-smokers.
    Eur Respir J. 2015 Dec 23. pii: ERJ-01524-2015. doi: 10.1183/13993003.01524-2015
    PubMed     Text format     Abstract available


  44. REMON J, Gorham J, Besse B, Sculier JP, et al
    Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients?
    Eur Respir J. 2015;46:1548-50.
    PubMed     Text format    


  45. CHAPUT N, Marabelle A
    Foxp3+ cells are running the show in patients with surgically resected nonsmall cell lung cancer.
    Eur Respir J. 2015;46:1541-3.
    PubMed     Text format    


    June 2015
  46. IZUMO T, Sasada S, Chavez C, Matsumoto Y, et al
    Radial endobronchial ultrasound images for ground-glass opacity pulmonary lesions.
    Eur Respir J. 2015;45:1661-8.
    PubMed     Text format     Abstract available


    March 2015
  47. INFANTE M
    A conservative approach for subsolid lung nodules: is it safe enough?
    Eur Respir J. 2015;45:592-5.
    PubMed     Text format    


  48. MEINERS S, Eickelberg O, Konigshoff M
    Hallmarks of the ageing lung.
    Eur Respir J. 2015;45:807-27.
    PubMed     Text format     Abstract available


    January 2015
  49. GERSHON AS, Mecredy GC, Guan J, Victor JC, et al
    Quantifying comorbidity in individuals with COPD: a population study.
    Eur Respir J. 2015;45:51-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: